These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32176394)

  • 1. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.
    Georgakopoulos JR; Lam K; Sandhu VK; Ighani A; Phung M; Piguet V; Yeung J
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e416-e418. PubMed ID: 32176394
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García E; Herrera-Ceballos E
    Dermatol Ther; 2020 Nov; 33(6):e14202. PubMed ID: 32808703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
    Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN
    PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
    Brunner PM; Conrad C; Vender R; Grond S; Schuster C; Patel H; Xu W; Carrascosa Carrillo JM
    Br J Dermatol; 2021 Oct; 185(4):865-867. PubMed ID: 34076896
    [No Abstract]   [Full Text] [Related]  

  • 7. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis.
    Puig L; Lomaga M; Hollister K; Dutronc Y; Berggren L; van de Kerkhof PCM
    Acta Derm Venereol; 2020 Dec; 100(19):adv00344. PubMed ID: 33236124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 10. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    López Jiménez P; Suárez Pérez J; Herrera Acosta E; Aguilera Arjona J; Mendiola Fernández MV; Bosch García R; Herrera Ceballos E
    Dermatol Ther; 2019 Jul; 32(4):e12937. PubMed ID: 30983098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
    Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
    Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
    Puig L; Augustin M; Blauvelt A; Gottlieb AB; Vender R; Korman NJ; Thaçi D; Zhao Y; Gilloteau I; Sherif B; Williams N; Guana A; Lebwohl MG
    J Am Acad Dermatol; 2018 Apr; 78(4):741-748. PubMed ID: 29066271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
    Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
    J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.